Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders

Marilyn Huckans, Aaron D. Blackwell, Todd A. Harms, Peter Hauser

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. Methods: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. Results: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalPsychiatric Services
Volume57
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Hepatitis C
schizophrenia
Substance-Related Disorders
contagious disease
Schizophrenia
Disease
Interferons
management
United States Department of Veterans Affairs
Control Groups
Group
Psychotic Disorders
Therapeutics
Delivery of Health Care
Infection

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. / Huckans, Marilyn; Blackwell, Aaron D.; Harms, Todd A.; Hauser, Peter.

In: Psychiatric Services, Vol. 57, No. 3, 03.2006, p. 403-406.

Research output: Contribution to journalArticle

Huckans, Marilyn ; Blackwell, Aaron D. ; Harms, Todd A. ; Hauser, Peter. / Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. In: Psychiatric Services. 2006 ; Vol. 57, No. 3. pp. 403-406.
@article{09cec4329aa440559f6204bdab8df1db,
title = "Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders",
abstract = "Objective: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. Methods: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. Results: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.",
author = "Marilyn Huckans and Blackwell, {Aaron D.} and Harms, {Todd A.} and Peter Hauser",
year = "2006",
month = "3",
doi = "10.1176/appi.ps.57.3.403",
language = "English (US)",
volume = "57",
pages = "403--406",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders

AU - Huckans, Marilyn

AU - Blackwell, Aaron D.

AU - Harms, Todd A.

AU - Hauser, Peter

PY - 2006/3

Y1 - 2006/3

N2 - Objective: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. Methods: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. Results: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.

AB - Objective: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. Methods: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. Results: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.

UR - http://www.scopus.com/inward/record.url?scp=33644838176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644838176&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.57.3.403

DO - 10.1176/appi.ps.57.3.403

M3 - Article

VL - 57

SP - 403

EP - 406

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 3

ER -